Key result
In E3L.CETP mice, combination therapy with torcetrapib and atorvastatin did not reduce atherosclerosis compared with atorvastatin alone and resulted in lesions of a more inflammatory phenotype.
Why the study?
Does torcetrapib alone or in combination with atorvastatin reduce atherosclerosis and alter plaque phenotype in E3L.CETP mice?
Does torcetrapib alone or in combination with atorvastatin reduce atherosclerosis and alter plaque phenotype in E3L.CETP mice?
Torcetrapib does not provide additional antiatherogenic benefits over atorvastatin and induces a more inflammatory, less stable plaque phenotype in mice, providing a potential mechanism for its clinical failure.
Answers are grounded in this paper and cite their sources.
Provides potential mechanism for torcetrapib failure; hypothesis-generating for CETP inhibition effects on human plaque stability.
BACKGROUND: Although cholesteryl ester transfer protein (CETP) inhibition is regarded as a promising strategy to reduce atherosclerosis by increasing high-density lipoprotein cholesterol, the CETP inhibitor torcetrapib given in addition to atorvastatin had no effect on atherosclerosis and even increased cardiovascular death in the recent Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events trial. Therefore, we evaluated the antiatherogenic potential and adverse effects of torcetrapib in humanized APOE*3-Leiden.CETP (E3L.CETP) mice. METHODS AND RESULTS: E3L.CETP mice were fed a cholesterol-rich diet without drugs or with torcetrapib (12 mg x kg(-1) x d(-1)), atorvastatin (2.8 mg x kg(-1) x d(-1)), or both for 14 weeks. Torcetrapib decreased CETP activity in both the absence and presence of atorvastatin (-74% and -73%, respectively; P<0.001). Torcetrapib decreased plasma cholesterol (-20%; P<0.01), albeit to a lesser extent than atorvastatin (-42%; P<0.001) or the combination of torcetrapib and atorvastatin (-40%; P<0.001). Torcetrapib increased high-density lipoprotein cholesterol in the absence (30%) and presence (34%) of atorvastatin. Torcetrapib and atorvastatin alone reduced atherosclerotic lesion size (-43% and -46%; P<0.05), but combination therapy did not reduce atherosclerosis compared with atorvastatin alone. Remarkably, compared with atorvastatin, torcetrapib enhanced monocyte recruitment and expression of monocyte chemoattractant protein-1 and resulted in lesions of a more inflammatory phenotype, as reflected by an increased macrophage content and reduced collagen content. CONCLUSIONS: CETP inhibition by torcetrapib per se reduces atherosclerotic lesion size but does not enhance the antiatherogenic potential of atorvastatin. However, compared with atorvastatin, torcetrapib introduces lesions of a less stable phenotype.
No takes yet. Share an insight, caveat, or question.
Haan et al. (2008) studied Atherosclerosis. Torcetrapib and atorvastatin vs. No drugs or atorvastatin alone was evaluated on Atherosclerotic lesion size (p=<0.05). In E3L.CETP mice, combination therapy with torcetrapib and atorvastatin did not reduce atherosclerosis compared with atorvastatin alone and resulted in lesions of a more inflammatory phenotype.
Synapse has enriched 10 related papers. Consider them for comparative context: